We are a global clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel biologic therapies , including “100% species-specific” products derived from our PETization™ technology.

PETization is designed to rapidly create monoclonal antibodies (“mAbs”) that are recognized as “self” by a patient’s immune system, a property we refer to as 100% species-specificity.

Our most advanced product candidate, ranevetmab, is a mAb being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in dogs. Our second product candidate, NV-02, is a mAb being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in cats.

We are also developing mAbs in the areas of immuno-oncology (cancer), chronic inflammation, and allergy.

We welcome you to learn more about us by reading the Nexvet team's vision for our future, and the future of animal healthcare.

Nexvet Biopharma

Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522 

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108

Email: info@nexvet.com

Get in Touch